Janet Woodcock (Photographer: Al Drago/Bloomberg via Getty Images)

Janet Wood­cock calls for in­de­pen­dent in­ves­ti­ga­tion in­to Bio­gen and FDA re­la­tion­ships in un­prece­dent­ed move

In the lat­est stun­ning chap­ter of the Bio­gen Aduhelm saga, act­ing FDA com­mis­sion­er Janet Wood­cock is call­ing for an in­ves­ti­ga­tion in­to the re­la­tion­ships be­tween agency of­fi­cials and Bio­gen ex­ec­u­tives.

Wood­cock an­nounced the move ear­ly Fri­day af­ter­noon, post­ing a let­ter to the act­ing HHS In­spec­tor Gen­er­al on Twit­ter.

The re­quest comes as con­tro­ver­sy con­tin­ues to swirl around the ap­proval, with promi­nent mem­bers of Con­gress launch­ing probes and Bio­gen tak­ing the ex­tra­or­di­nary step this week to ask for a nar­row­er drug la­bel. Wood­cock’s call for a probe al­so comes less than two weeks af­ter a re­port from STAT News high­light­ed a ma­jor un­der­tak­ing from Bio­gen to get Aduhelm ap­proved that be­gan as ear­ly as 2019.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.